# Editorial: Supreme Court flags ten-fold drug markups, exposing gaps in price control

URL: https://upsc.help/current-affairs/2026-10-01/drug-markups-bitter-pills-editorial/
Date: 1 October 2026 (2026-10-01)
Source: The Hindu, Editorial
UPSC papers: GS2, GS3
Publisher: upsc.help (Pratidin), free and open-source UPSC Civil Services current affairs. Not affiliated with UPSC. Every fact was checked against the source reports by a separate review before publishing.

**In one line:** The Supreme Court has questioned why some medicines, including cancer drugs, reach patients at up to ten times what chemists pay, and The Hindu's editorial uses this to examine India's drug price regime.

The Hindu's editorial 'Bitter pills' (1 October 2026) takes up a Supreme Court hearing on drug prices. It notes that the Court 'has upbraided disparities between the price to retailer (PTR) and the maximum retail price (MRP) of certain drugs, including those used to treat cancers, in some instances up to 1,000%'. The PTR is what the chemist pays the company; the MRP is the most the patient can be charged. On 29 September 2026, a Bench of Justices Vikram Nath and Sandeep Mehta, hearing petitions by Kishan Chand Jain and others, was shown a cancer medicine with a PTR of about ₹2,700 and an MRP of about ₹27,000. 'This is carnage. Plain and simple,' the Bench said.

The legal frame is the Drugs (Prices Control) Order, 2013 (DPCO), issued under Section 3 of the Essential Commodities Act, 1955. For 'scheduled' medicines, those in the National List of Essential Medicines, the National Pharmaceutical Pricing Authority (NPPA) fixes a ceiling price: the simple average of the PTRs of brands with at least 1% market share, plus a 16% retailer margin. 'Non-scheduled' medicines, about four-fifths of the market by value, have no ceiling; companies may only raise their MRP by up to 10% a year. The Bench asked why the 16% margin should not apply to everything: 'Essential or non-essential does not matter?' It asked where 'this huge chunk of money' goes, and asked the Centre to examine hospitals that make patients buy from in-house pharmacies.

Solicitor General Tushar Mehta said, 'I am not saying the petitioners are wrong, but some way which balances equities will have to be found.' He is to hold talks with officials within two weeks, and the case returns on 12 October. At an earlier hearing on 22 September the Court had called the practice 'broad daylight dacoity'. The government has used the DPCO's extraordinary powers before: in February 2019 the NPPA capped trade margins on 42 non-scheduled anti-cancer drugs at 30%. In August 2026 it was reported to be weighing trade margin rationalisation within the DPCO itself. Data reported then suggested very high markups were concentrated in a small share of the market, which is the core of the debate: a blanket cap versus targeted control.

## Prelims facts

- The DPCO, 2013 is issued under Section 3 of the Essential Commodities Act, 1955 and is administered by the NPPA.
- Ceiling price of a scheduled medicine = simple average PTR of brands with at least 1% market share, plus a 16% retailer margin.
- Makers of non-scheduled medicines may raise MRP by at most 10% in a year; there is no ceiling price.
- On 29 September 2026 the Supreme Court (Justices Vikram Nath and Sandeep Mehta) asked why the 16% margin cannot apply to all medicines; next hearing 12 October.
- In February 2019, using paragraph 19 of the DPCO, the NPPA capped trade margins on 42 non-scheduled anti-cancer drugs at 30%.

## Quick recall

- **Parent law of the DPCO, 2013** Section 3 of the Essential Commodities Act, 1955.
- **Retailer margin added in DPCO ceiling price formula** 16%.
- **Market-share cut-off for brands in the ceiling price average** At least 1% of the medicine's market.
- **Maximum annual MRP increase for non-scheduled medicines** 10%.
- **Body that fixes and enforces drug ceiling prices** National Pharmaceutical Pricing Authority (NPPA).
- **Trade margin cap of February 2019** 30% on 42 non-scheduled anti-cancer drugs, using paragraph 19 of the DPCO.
- **Bench in the September 2026 drug markup hearing** Justices Vikram Nath and Sandeep Mehta.
- **PTR** Price to retailer: what the chemist or hospital pharmacy pays the supplier.

## Prelims practice question

Under the Drugs (Prices Control) Order, 2013, the ceiling price of a scheduled formulation is calculated by:

(a) Adding a 16% retailer margin to the simple average price to retailer of brands with at least 1% market share
(b) Adding a 30% trade margin to the price to stockist of the lowest-priced brand
(c) Taking the cost of production of the market leader plus a fixed profit
(d) Allowing the maximum retail price to rise by up to 10% each year

Answer: (a) Adding a 16% retailer margin to the simple average price to retailer of brands with at least 1% market share. Paragraph 4 of the DPCO takes the simple average PTR of all brands and generics with at least 1% market share and adds a 16% retailer margin. The 30% trade-margin cap was the 2019 measure for 42 anti-cancer drugs; the 10% annual increase rule applies to non-scheduled medicines.

## UPSC previous-year questions this connects to

- UPSC Mains 2024, GS2: In a crucial domain like the public healthcare system the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level. (https://upsc.help/pyq/q174-crucial-domain-like-public-healthcare-system-indian/)
  How to use this story in the answer: Use the cancer-drug markup case as a stark example of marketisation in health care, and margin control plus generics as state measures to contain it.
- UPSC Mains 2015, GS2: Public health system has limitation in providing universal health coverage. Do you think that private sector can help in bridging the gap? What other viable alternatives do you suggest? (https://upsc.help/pyq/q173-public-health-system-has-limitation-providing-universal/)
  How to use this story in the answer: Use it to show that private provision of medicines needs regulation before it can help universal coverage, and to suggest pricing and generic alternatives.

## Mains practice question

High trade margins on medicines undermine the right to health even when prices are regulated. Examine the drug price control framework in India and suggest reforms. (250 words)

### Model answer

In September 2026 the Supreme Court called ten-fold markups on some cancer drugs 'carnage', exposing gaps in India's drug price control framework.

## The framework
- **DPCO, 2013**, under Section 3 of the Essential Commodities Act, 1955, administered by the NPPA.
- **Scheduled medicines** (in the National List of Essential Medicines): ceiling price = average PTR of brands with at least 1% market share plus 16% retailer margin.
- **Non-scheduled medicines**: no ceiling; MRP may rise by at most 10% a year.
- **Paragraph 19**: extraordinary powers, used in 2019 to cap trade margins on 42 anti-cancer drugs at 30%.

## Gaps
- About four-fifths of the market by value is non-scheduled, so most medicines have no price ceiling.
- Price control acts on the ceiling, not the margin: a company can set a high MRP and offer a low PTR, giving retailers and hospitals a large cut.
- Hospitals that require purchases from in-house pharmacies leave patients no choice.
- High out-of-pocket spending on medicines pushes households into poverty.

## Reforms
- Bring trade margin rationalisation into the DPCO, with caps graded by price band.
- Wider and faster revision of the National List of Essential Medicines.
- Expand Jan Aushadhi generic outlets and enforce prescription by generic name.
- Transparency: print PTR alongside MRP; let patients buy from any pharmacy.
- Stronger NPPA monitoring and recovery of overcharged amounts.
- Prefer targeted caps on outliers if blanket caps threaten supply.

Affordable medicines are central to the right to health under Article 21, and margin control is the missing piece in India's price regime.

## The basics

## Why this matters
Medicines are one of the largest parts of what Indian families pay for health care out of their own pockets. India regulates some drug prices, but the Supreme Court's hearing shows that the gap between what the chemist pays and what the patient pays can be enormous.

## The supply chain in brief
A company sells to a stockist, the stockist to a retailer (chemist or hospital pharmacy), and the retailer to the patient. The **PTR** is what the retailer pays. The **MRP**, printed on the pack, is the most the patient can be charged. The difference is the retailer's margin.

## Two kinds of medicines
The Drugs (Prices Control) Order, 2013 treats medicines differently depending on whether they are on the National List of Essential Medicines.

## How a ceiling price is set

## The missing lever: margins
Price control caps the MRP, not the margin. A company can keep a high MRP and offer a low PTR so that chemists or hospitals earn more by stocking its brand. Trade Margin Rationalisation caps the gap directly. It was used for 42 anti-cancer drugs in 2019 under the DPCO's emergency power. The parent law is the Essential Commodities Act, 1955.

## Sources

- https://www.editorialwords.com/the-hindu-editorial-bitter-pills-oct-01-2026/
- https://www.verdictum.in/supreme-court/markup-of-ten-times-on-cancer-drugs-1622986
- https://www.onmanorama.com/news/india/2026/09/30/supreme-court-uniform-medicine-margin.html
- https://www.business-standard.com/amp/india-news/sc-flags-a-costly-dose-of-markups-asks-for-16-cap-on-essential-meds-126092901143_1.html
- https://www.business-standard.com/amp/industry/news/govt-weighs-incorporating-trade-margin-rationalisation-into-dpco-126080701597_1.html
- https://www.mondaq.com/india/healthcare/791012/india-puts-42-non-scheduled-cancer-drugs-under-price-control
